369TiP PATINA: A randomized, open label, phase III trial to evaluate the efficacy and safety of palbociclib+ Anti-HER2 therapy+ endocrine therapy (ET) vs. anti-HER2 therapy+ ET after induction treatment for hormone receptor positive (HR+)/HER2-positive metastatic breast cancer (MBC)